<DOC>
	<DOC>NCT02803177</DOC>
	<brief_summary>In the present phase-II clinical trial the researchers investigate efficacy and proof of concept of the augmentation with preoperatively isolated autologous BMC cells seeded onto ß-TCP in combination with an angle stable fixation (Philos plate®) for the therapy of proximal humeral fractures.</brief_summary>
	<brief_title>Cell Therapy by Autologous BMC for Large Bone Defect Repair</brief_title>
	<detailed_description />
	<mesh_term>Fractures, Bone</mesh_term>
	<mesh_term>Humeral Fractures</mesh_term>
	<criteria>patients aged between 50. and 90. years with proximal humerus fractures indication for open reposition and internal stabilisation with a proximal fixed angle plate for humerus (PHILOS, Synthes, Oberdorf, Swiss): 2, 3 or 4fragment fracture according to Neer dislocation of &gt;10 mm between fragments and/or angle of &gt; 45° between fragments and/or dislocation of tuberculum majus &gt; 5 mm negative pregnancy test of premenopausal women signed informed consent for surgery and participation in the clinical trial contraindications against administration of Investigational medicinal product (IMP) is pregnancy and nursing dislocation fracture known psychic disorder that leads to incompliance (e.g. dementia, schizophrenia, major depression) pathologic fractures caused by other underlying diseases fractureinduced nerve damage tumor disease with recent adjuvant therapy or treatment during the last 3 months (e.g. chemotherapy, radiotherapy), untreated tumor diseases known hypersensibility against components of the transplant participation in a clinical trial during the last 3 months prior to this study</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>large bone defect</keyword>
	<keyword>bone marrow-derived mononuclear cells</keyword>
</DOC>